100 Or More Amino Acid Residues In The Peptide Chain Patents (Class 514/21.2)
-
Patent number: 8450273Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.Type: GrantFiled: April 9, 2008Date of Patent: May 28, 2013Assignees: The Board of Trustees of the University of Arkansas, Ochsner Clinic Foundation, National University Corporation Kagawa UniversityInventors: Joshua Sakon, Robert C. Gensure, Osamu Matsushita
-
Publication number: 20130129751Abstract: The present disclosure includes methods and compositions for treating any condition involving prostatitis and similar diseases and/or conditions. These methods and compositions involve the use of targeted modified pore-forming proteins, including variant proaerolysin proteins.Type: ApplicationFiled: September 10, 2012Publication date: May 23, 2013Applicant: PROTOX THERAPEUTICS CORP.Inventor: J. Curtis Nickel
-
Patent number: 8445445Abstract: The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 4 (FGFR4) extracellular domain (ECD), including native FGFR4 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.Type: GrantFiled: September 15, 2010Date of Patent: May 21, 2013Assignee: Five Prime Therapeutics, Inc.Inventors: Thomas Brennan, Robert Dean, W. Michael Kavanaugh, Janine Powers
-
Patent number: 8445447Abstract: Compositions and methods for costimulating T cells (i.e., increasing antigen-specific proliferation of T cells, enhancing cytokine production by T cells, stimulating differentiation ad effector functions of T cells and/or promoting T cell survival) are provided. Suitable compositions include variant B7-DC polypeptides, fragments and fusion proteins thereof. Variant B7-DC polypeptides have reduced binding affinity for the inhibitory PD-1 ligand and substantially retain the ability to costimulate T cells. Methods for using variant B7-DC polypeptides to stimulate immune responses in subjects in need thereof are provided.Type: GrantFiled: March 7, 2012Date of Patent: May 21, 2013Assignee: The Johns Hopkins UniversityInventor: Lieping Chen
-
Publication number: 20130121958Abstract: The present invention provides an innovative versatile system, which allows delivery of one or several antigens or biologically active molecules into or onto targeted subset of cells. The invention is in particular directed to a combination of compounds and in particular to a composition, which comprises: (i) a fusion polypeptide comprising a streptavidin (SA) or avidin polypeptide and one or several effector molecule(s), wherein said fusion polypeptide retains the property of SA and avidin polypeptides to bind biotin; (ii) biotinylated targeting molecule(s), which are capable of targeting subset(s) of cells and/or cell surface molecule(s), and in particular dendritic cells (DC), subsets of DC and/or surface molecule(s) (including surface receptor(s)) of DC.Type: ApplicationFiled: December 12, 2010Publication date: May 16, 2013Applicants: INSTITUTE OF MICROBIOLOGY OF THE ASCR., V.V.I., INSTITUT PASTEURInventors: Claude Leclerc, Laleh Majlessi, Hui Dong, Peter Sebo, Ondrej Stanek
-
Publication number: 20130123199Abstract: A protein complex comprising an in vitro stabilization protein, a membrane translocation sequence domain, a biologically active molecule, and an in vivo stabilization protein, as well as methods for the use and production thereof.Type: ApplicationFiled: August 16, 2012Publication date: May 16, 2013Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventor: Jae-il LEE
-
Publication number: 20130123198Abstract: Compositions and kits for modulating expression of scleraxis and/or collagen synthesis in mammalian cells and tissues. The compositions and kits comprise a protein comprising an amino acid sequence that shares at least 75% homology with SEQ ID NO:11. Proteins comprising amino acid sequences that share at least 75% homology with SEQ ID NO: 11 are expressed by mutants of scleraxis gene wherein a nucleotide sequence comprising a basic DNA binding domain has been deleted. Such mutants are exemplified by basic domain deletion Scx?BD mutants that comprise nucleotide sequences sharing at least 75% homology with SEQ ID NO:8 or SEQ ID NO: 10. Methods for modulating fibrosis in a subject comprising administration of a composition comprising at least one physiologically effective dosage of a protein comprising a polypeptide molecule comprising an amino acid sequence that shares at least 75% homology with SEQ ID NO: 11.Type: ApplicationFiled: May 10, 2011Publication date: May 16, 2013Applicant: UNIVERSITY OF MANITOBAInventor: Michael P. Czubryt
-
Publication number: 20130123200Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.Type: ApplicationFiled: January 15, 2013Publication date: May 16, 2013Applicant: Merck Sharp & Dohme Corp.Inventor: Merck Sharp & Dohme Corp.
-
Publication number: 20130116167Abstract: The invention provides a chimeric T cell receptor (TCR) comprising a variable region of a human TCR and a constant region comprising at least an extracellular domain of a constant region of a non-human TCR, as well as functional variants thereof. The invention also provides polypeptides and proteins related to the inventive TCRs, as well as nucleic acids encoding the TCRs, polypeptides, or proteins, recombinant expression vectors, and host cells. Further provided are pharmaceutical compositions related to the inventive TCRs and methods of preventing or treating a disease, e.g., an infectious disease, cancer, in a host, methods of detecting a diseased cell in a host, and methods of improving the biological activity of a TCR.Type: ApplicationFiled: November 2, 2012Publication date: May 9, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health & Human ServicInventor: The United States of America, as represented by
-
Publication number: 20130116201Abstract: The method pertains to a peptide including the amino acid sequence SEQ ID NO: 1, or a peptide including an amino acid sequence having 93%, in particular 95%, particularly 98% sequence identity homology with the sequence SEQ ID NO: 1, in order to obtain a transporter intended for the internalization of a molecule of diagnostic or therapeutic interest into the target cells.Type: ApplicationFiled: April 7, 2011Publication date: May 9, 2013Applicant: UNIVERSITE JOSEPH FOURIERInventors: Jean-Luc Lenormand, Romy Rothe Walther
-
Patent number: 8435952Abstract: The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.Type: GrantFiled: February 10, 2011Date of Patent: May 7, 2013Inventors: George Vratsanos, Jean-Claude Becker, Michael Corbo
-
Patent number: 8435951Abstract: The present invention provides a method of treating a cancer using a neurotoxin, preferably Botulinum toxin (“BTX”). The application of a neurotoxin around a cancer acts to decrease the contractile forces of the muscles surrounding a neoplasm which normally squeeze cancer cells through efferent channels leaving the cancer vicinity to distant sites. Also, the application of the toxin at sites distant from the cancer enhances cellular and humoral immunologic functions which further contributes to cancer cell death and spread. Following administration of botulinum toxin around and distant to a cancer, it is noticed that local, regional, and distant spread is reduced or eliminated. Immunomodulation with botulinum toxin is also valuable in treating other disease that may or may not be associated with cancers, such as viral-induced growths, viral conditions, fungal disease, chronic wounds, graft versus host disease, autoimmune disease, and HIV.Type: GrantFiled: March 17, 2010Date of Patent: May 7, 2013Assignee: Toxcure, Inc.Inventor: Christopher Shaari
-
Publication number: 20130109634Abstract: The present disclosure relates to a casein peptide for use in the treatment of an uterine infection in a female mammalian animal, to methods of treatment of such infections by administering to a female mammalian animal at least one casein peptide, to the use of casein peptide for the preparation of a pharmaceutical composition for treatment of uterine infection and to a kit for said treatment. The casein peptide is preferably a casein hydrolysate, e.g. obtained by trypsin hydrolysis of casein protein. The female mammalian animal is, in accordance with some embodiments, a lactating animal, the infection being a post-partum infection.Type: ApplicationFiled: April 17, 2011Publication date: May 2, 2013Inventor: Jose Mario Iscovich
-
Publication number: 20130108602Abstract: Methods of decreasing, reducing, inhibiting, suppressing, limiting or controlling an undesirable or aberrant immune response, immune disorder, inflammatory response, or inflammation in a subject; decreasing, reducing, inhibiting, suppressing, limiting or controlling an autoimmune response, disorder or disease in a subject; and decreasing, reducing, inhibiting, suppressing, limiting or controlling an adverse cardiovascular event or cardiovascular disease in a subject, are provided. Methods include, for example, administering a Nur77 polypeptide or subsequence thereof, a Nur77 agonist, or CD14+ CD16+ monocytes or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes or macrophages to a subject to decrease, reduce, inhibit, suppress, limit or control the underlying condition or an adverse symptom or pathology of the condition.Type: ApplicationFiled: October 5, 2012Publication date: May 2, 2013Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGYInventor: LA JOLLA INSTITUTE FOR ALLERGY AND IMMU
-
Patent number: 8431124Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.Type: GrantFiled: April 16, 2009Date of Patent: April 30, 2013Assignee: Halozyme, Inc.Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
-
Patent number: 8431532Abstract: Methods of treatment using Fzd8 extracellular domains (ECDs), Fzd8 ECD fusion molecules, and/or antibodies that bind Fzd8 are provided. Such methods include, but are not limited to, methods of treating obesity and obesity-related conditions. Fzd8 ECDs and Fzd8 ECD fusion molecules are also provided. Polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules are provided. Methods of making and using Fzd8 ECDs, Fzd8 ECD fusion molecules, and antibodies that bind Fzd8 are also provided.Type: GrantFiled: June 27, 2011Date of Patent: April 30, 2013Assignee: Five Prime Therepeutics, Inc.Inventors: Thomas Brennan, Ernestine Lee, Steven Smith
-
Publication number: 20130102542Abstract: The invention is related to isoforms of components of transcription factor complexes that are specifically expressed in cancer cells. These isoforms can be used as biomarkers for detection, diagnosis, prognosis and monitoring of treatments of cancer, and as drug targets of pharmaceutical compositions for the treatment of various cancers expressing the targeted isoforms. Methods, molecules, materials and kits for these uses are disclosed.Type: ApplicationFiled: October 17, 2012Publication date: April 25, 2013Applicant: ONCOTX, INC.Inventor: Oncotx, Inc.
-
Patent number: 8420088Abstract: The present invention is directed to fusion polypeptides comprising Klotho protein or an active fragment thereof and FGF23 or an active fragment thereof.Type: GrantFiled: January 29, 2010Date of Patent: April 16, 2013Assignee: Novartis AGInventors: David Glass, Shou-Ih Hu
-
Patent number: 8420779Abstract: Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10th fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of IgG1, a PDZ domain, a thrombospondin repeat domain, an ubiquitin domain, a leucine-rich repeat domain, a villin headpiece HP35 domain, a villin headpiece HP76 domain, or a fragment or modification of any of these. Also disclosed are nucleic acids (e.g., DNA constructs) encoding the fusion protein, expression vectors and recombinant host cells for expression of the fusion protein, and pharmaceutical compositions containing the recombinant fusion protein and a pharmaceutically acceptable carrier, and method of producing a pharmacologically active recombinant fusion protein.Type: GrantFiled: May 22, 2008Date of Patent: April 16, 2013Assignee: Amgen Inc.Inventors: Kenneth W. Walker, Colin V. Gegg, Jr.
-
Patent number: 8420106Abstract: A method for selection and treatment of externally caused migraine headache, the method includes identifying a patient group having chronic migraine headache; determining the identified patient group, a specific patient with a post traumatic migraine headache; and administering to the selected patient by injection of a therapeutically effective amount of a Botulinum neurotoxin in a pharmaceutically safe form to the selected patient's head or upper neck; administration preferably being on the sites of the trigeminal cervical system, enabling axonal transport of the neurotoxin from distal to central sites; and the administration preferably comprising extramuscular injection of the neurotoxin of suitable dilution (a) over the aponeurotic fascia, or (b) intra-orally, in a foramina of the sphenopalatine ganglion, or (c) to emerging exit points of nerves including foraminal sites.Type: GrantFiled: May 23, 2012Date of Patent: April 16, 2013Inventor: William J. Binder
-
Biocompatible materials containing stable complexes of TSG-6 and hyaluronan and method of using same
Patent number: 8420601Abstract: The present invention provides a biocompatible material in the form of a water insoluble cross-linked gel, which contains a stable complex of TNF-stimulated gene 6 protein (TSG-6) and hyaluronan.Type: GrantFiled: November 18, 2011Date of Patent: April 16, 2013Assignees: New York University, Polytechnic Institute of NYUInventors: Hans-Georg Wisniewski, Mary K. Cowman, Philip Band -
Patent number: 8420094Abstract: The invention features recombinant exotoxins from Vibrio cholerae are for the therapeutic treatment of a variety of human diseases, particularly diseases characterized by an abundance or excess of undesired cells.Type: GrantFiled: July 18, 2008Date of Patent: April 16, 2013Assignee: The General Hospital CorporationInventors: Brian Seed, Jia Liu Wolfe, Chia-Lun Tsai
-
Publication number: 20130090294Abstract: The present invention relates to novel therapies that utilize exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of exogenous HSP70.Type: ApplicationFiled: June 28, 2012Publication date: April 11, 2013Applicant: ALTERNATIVE INNOVATIVE TECHNOLOGIES LLCInventors: Sergei B. Onikienko, Alex Nivorozhkin, Alexander V. Zemlyanoi
-
Patent number: 8414876Abstract: Methods of treating, inhibiting, or ameliorating an autoinflammatory disorder, disease, or condition in a subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the autoinflammatory disorder, disease, or condition is treated, inhibited, or ameliorated. The IL-1 antagonist is a molecule capable of binding and inhibiting IL-1. The therapeutic methods are useful for treating a human adult or child suffering from Neonatal Onset Multisystem Inflammatory Disorder (NOMID/CINCA), Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS), familial mediterranean fever (FMF), tumor necrosis factor receptor-associated periodic fever syndrome (TRAPS), or systemic onset juvenile idiopathic arthritis (Still's Disease).Type: GrantFiled: September 2, 2011Date of Patent: April 9, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Scott Mellis, Margaret Karow, George D. Yancopoulos, Joanne Papadopoulos
-
Patent number: 8415455Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: GrantFiled: September 3, 2008Date of Patent: April 9, 2013Assignee: Compugen LtdInventors: Zurit Levine, Tania Pergam, Dalit Landesman-Milo, Anat Cohen-Dayag, Amir Toporik, Yaron Kinar, Sergey Nemzer, Avi Rosenberg, Galit Rotman, Amit Novik, Cynthia Koifman, Merav Beiman, Liat Dassa, Shira Walach, Eve Montia, Shirley Sameach-Greenwald, Ofer Levy, Marina Bubis
-
Patent number: 8415303Abstract: The present invention relates to nucleotide sequences of vertebrate Delta genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the vertebrate Delta protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of Delta which comprise one or more domains of the Delta protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, domain amino-terminal to the DSL domain, transmembrane region, or one or more EGF-like repeats of a Delta protein, or any combination of the foregoing. Antibodies to Delta, its derivatives and analogs, are additionally provided. Methods of production of the Delta proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided.Type: GrantFiled: October 10, 2006Date of Patent: April 9, 2013Assignees: Imperial Cancer Research Technology, Ltd., Yale UniversityInventors: David Ish-Horowicz, Domingos Manuel Pinto Henrique, Julian Hart Lewis, Spyridon Artavanis-Tsakonas, Grace E. Gray
-
Publication number: 20130085113Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.Type: ApplicationFiled: June 8, 2011Publication date: April 4, 2013Inventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
-
Publication number: 20130084292Abstract: An antagonist of the interaction between the Gp96 receptor and E. coli AIEC strains, for the prevention or treatment of inflammatory bowel disease. The antagonist is for specifically blocking or reducing the interaction between Gp96 receptor and the outer membrane vesicles (OMVs), typically the outer protein membrane OmpA of E. coli AIEC strains. The inventions provides for pharmaceutical compositions containing such an antagonist, which may be an antibody against gp96 or OmpA, or a gp96 or OmpA polypeptide. It may be combined to an antagonist of the interaction between the CEACAM6 receptor and E. coli AIEC strains, such as an anti-CEACAM6 antibody, a CEACAM6 polypeptide, or a mannoside or particle having a mannose unit. The invention also relates to a method for the diagnosis of inflammatory bowel disease, or of the determination of a predisposition of a person to develop inflammatory bowel disease.Type: ApplicationFiled: April 15, 2011Publication date: April 4, 2013Applicant: UNIVERSITE D'AUVERGNE CLERMONT IInventors: Arlette Darfeuille-Michaud, Paul Hofman, Nathalie Rolhion
-
Publication number: 20130084247Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The cargo compound may be a nucleic acid and specifically a DNA, RNA or anti-sense. The invention further discloses methods for treating cancer and diagnosing cancer.Type: ApplicationFiled: July 30, 2012Publication date: April 4, 2013Applicant: The Board of Trustees of the University of IllinoisInventors: Tapas Das Gupta, Ananda Chakrabarty, Craig Beattie, Tohru Yamada
-
Patent number: 8410060Abstract: The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNF? by administering a TNF? antagonist, such as recombinant TNFR:Fc.Type: GrantFiled: February 6, 2012Date of Patent: April 2, 2013Assignee: Immunex CorporationInventor: Barbara K. Finck
-
Patent number: 8410058Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.Type: GrantFiled: April 1, 2011Date of Patent: April 2, 2013Assignee: MedImmune LimitedInventors: Olivia Raeber, Gadi Gazit-Bornstein, Xiao-Dong Yang, Susan Ann Cartlidge, David William Tonge
-
Publication number: 20130078253Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: March 30, 2012Publication date: March 28, 2013Applicant: CELERA CORPORATIONInventors: Dong FANG, Paul MOORE, Steve RUBEN, Sudeepta AGGARWAL
-
Patent number: 8404814Abstract: The present invention relates to fusion proteins comprising an antibody, functional fragment or functional derivative thereof having specific binding affinity to either the extracellular domain of oncofetal fibronectin (ED-B) or at least one of the extracellular domains of oncofetal tenascin fused to a cytokine selected from the group consisting of IL-10, IL15, IL-24 and GM-CSF, functional fragments and functional derivatives thereof. The invention is also directed to the use of at least one of said fusion proteins for the manufacture of a medicament. In particular, the invention concerns the use of said medicament for the treatment of tumors or chronic inflammatory diseases such as atherosclerosis, arthritis and psoriasis.Type: GrantFiled: May 8, 2007Date of Patent: March 26, 2013Assignee: Philogen SpAInventors: Dario Neri, Manuela Kaspar, Eveline Trachsel
-
Patent number: 8404642Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.Type: GrantFiled: October 3, 2011Date of Patent: March 26, 2013Assignee: NsGene A/SInventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
-
Patent number: 8404226Abstract: Methods and compositions are provided for treating a mammal having inflammation by protecting or enhancing a responsive cell, tissue, organ or body part exhibiting or associated with the inflammation, by systemic or local administration of a composition comprising a tissue protective cytokine. The invention also encompasses combination treatments comprising administering a composition comprising a tissue protective cytokine of the invention and administering at least one anti-inflammatory or least one immunomodulatory agent.Type: GrantFiled: July 3, 2003Date of Patent: March 26, 2013Assignee: The Kenneth S. Warren Institute, Inc.Inventors: Michael Brines, Anthony Cerami, Carla Cerami
-
Patent number: 8404644Abstract: The invention relates to the use of angiogenic crystallin proteins to promote angiogenesis, wound healing and/or endothelial cell migration. Alpha A crystallin and ?B2 crystallin have particular application in these methods. The crystallins will usually be in monomeric form. Typically, truncated form(s) of ?B2 crystallin protein are utilized as can be prepared by partial hydrolysis of the protein by a protease enzyme such as elastase I. Methods for the purification of crystallin proteins from eye tissue are also described.Type: GrantFiled: September 5, 2008Date of Patent: March 26, 2013Assignees: Meat & Livestock Australia Limited, Industrial Research LimitedInventors: Keryn Johnson, Madhusudan Vasudevamurthy
-
Publication number: 20130072445Abstract: The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the treatment of various disease states and conditions associated with SLE, including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions including hemolytic anemia and low lymphocyte counts, lymphadenopathy and CNS effects, including memory loss, seizures and psychosis, among numerous others as otherwise disclosed herein. In another aspect of the invention, the reduction in the likelihood that a patient who is at risk for an outbreak of a disease state or condition associated with SLE will have an outbreak is an additional aspect of the present invention. The present invention relates to the use of mutant Y175L CRP or L176E CRP in the treatment of a number of disease states or conditions that occur secondary to systemic lupus SLE.Type: ApplicationFiled: June 2, 2009Publication date: March 21, 2013Inventors: Terry W. Du Clos, Carolyn Mold
-
Publication number: 20130072429Abstract: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of GalNac-T related molecules, such as GalNac-T14 or GalNac-T3, is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Kits and articles of manufacture are also provided.Type: ApplicationFiled: April 11, 2012Publication date: March 21, 2013Applicant: Genentech, Inc.Inventors: Avi J. Ashkenazi, Klaus W. Wagner
-
Patent number: 8399405Abstract: Biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides; and methods of making and identifying such improved polypeptides.Type: GrantFiled: February 3, 2012Date of Patent: March 19, 2013Assignee: Aileron Therapeutics, Inc.Inventors: Huw M. Nash, David Allen Annis, Rosana Kapeller-Libermann, Tomi K. Sawyer, Noriyuki Kawahata
-
Publication number: 20130064866Abstract: The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided.Type: ApplicationFiled: September 7, 2012Publication date: March 14, 2013Applicant: Promedior, Inc.Inventors: W. Scott Willett, Richard J. Caimi, Lynne Anne Murray
-
Publication number: 20130065817Abstract: Disclosed is a polypeptide of use in the development of reagents or medicines favourable to application for prevention or treatment of ischemic disorders such as conditions caused by ateriosclerosis. The polypeptide has at least one part containing an amino acid of sequence ID 1, and also enhances expression levels of the amino acid in mammalian blood vessels removed from ischemic conditions by means of blood reperfusion.Type: ApplicationFiled: March 4, 2010Publication date: March 14, 2013Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Nobutaka Wakamiya, Katsuki Otani
-
Publication number: 20130064828Abstract: The invention described herein relates to a chimeric protein comprising the NTHi twitching pilus major subunit protein (PilA) presenting a portion of the NTHi OMP P5 protein. The invention provides for vaccine compositions comprising the recombinant chimeric protein and methods of eliciting an immune response using the recombinant chimeric proteins of the invention.Type: ApplicationFiled: September 10, 2012Publication date: March 14, 2013Applicant: Nationwide Children's Hospital, Inc.Inventors: Lauren O. Bakaletz, Robert S. Munson, JR.
-
Publication number: 20130065821Abstract: A method for improving blood HDL/LDL cholesterol ratio, reducing blood triglyceride level, reducing blood sugar level, and/or reducing body weight, that includes ingesting a composition containing a concentrated soybean germ product. The soybean germ product includes soybean germ protein; 1.0% by weight or less of saponin relative to the total weight of the soybean germ product; and 0.5% by weight or less of isoflavone relative to the total weight of the soybean germ product.Type: ApplicationFiled: October 16, 2012Publication date: March 14, 2013Applicant: J-OIL MILLS, INC.Inventor: J-OIL MILLS, INC.
-
Publication number: 20130067608Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: August 16, 2012Publication date: March 14, 2013Applicant: CELERA CORPORATIONInventors: Bruno DOMON, Aiqun LI, Tao HE, Ian MCCAFFERY
-
Patent number: 8394771Abstract: The invention provides multimerization polypeptides capable of conferring formation of multimers when the multimerization polypeptide is linked to a molecule, such as a heterologous polypeptide sequence.Type: GrantFiled: October 3, 2007Date of Patent: March 12, 2013Assignee: Perlan Therapeutics, Inc.Inventors: Fang Fang, Guang-Xiang Luo, Lori Allison Kohlstaedt, Catherine Helen Charles
-
Publication number: 20130058871Abstract: A mammalian Green Fluorescent Protein (GFP) Reconstruction Across Synaptic Partners (mGRASP) method and system is provided by optimizing synaptic transmelectron microscopicbrane carriers for mammalian synapses. The method and system in one form integrates molecular and cellular approaches with a novel computational strategy to reliably reconstruct neurons in 3D. The method and system allows mGRASP to be applied to both long-range and local microcircuits, analysis of synaptic distribution at the level of single neurons and dendritic compartments within neural cells.Type: ApplicationFiled: July 30, 2012Publication date: March 7, 2013Applicant: Howard Hughes Medical InstituteInventor: Jinhyun Kim
-
Patent number: 8388963Abstract: This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations.Type: GrantFiled: July 24, 2009Date of Patent: March 5, 2013Assignees: Aventis Pharma SA, Regeneron Pharmaceuticals IncInventors: Patricia Vrignaud, Marielle Chiron-Blondel, Marie-Christine Bissery, Eric Furfine, Jocelyn Holash, Jesse M. Cedarbaum
-
Patent number: 8389468Abstract: The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may be caused by or a cause of a variety of other conditions which are also encompassed by the present invention, such as viral and bacterial infections. Furthermore, the invention relates to a method for the treatment and/or prevention of compartment syndrome in a mammal in need thereof.Type: GrantFiled: February 11, 2011Date of Patent: March 5, 2013Assignee: Lantmannen AS-Faktor ABInventors: Hans-Arne Hansson, Stefan Lange, Eva Jennische, Tomas Bergström
-
METHODS OF INHIBITING APOPTOSIS OR INFLAMMATION IN A MAMMAL BY ADMINISTERING AN ISOLATED BCL PROTEIN
Publication number: 20130053329Abstract: In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal.Type: ApplicationFiled: October 26, 2012Publication date: February 28, 2013Applicant: UNIVERSITY OF WASHINGTONInventor: University of Washington -
Patent number: 8383575Abstract: A complex comprising barnase bound with high affinity to barstar, and comprising a therapeutic and/or diagnostic agent bound to barnase and/or barstar.Type: GrantFiled: January 31, 2005Date of Patent: February 26, 2013Assignee: Paul Scherrer InstitutInventors: Sergey Deyev, Robert Waibel, Andreas Plueckthun